Heron Therapeutics (HRTX) CEO exercises 13,797 RSUs into common stock
Rhea-AI Filing Summary
Heron Therapeutics, Inc. CEO Craig A. Collard exercised 13,797 restricted stock units into 13,797 shares of common stock on 2026-07-19. After this derivative conversion, he directly holds 771,682 common shares and 82,781 restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 13,797 shares
Net Buy
2 txns
Insider
Collard Craig A
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F2 | 13,797 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 13,797 | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 82,781 shares (Direct);
Common Stock — 771,682 shares (Direct)
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).
Key Figures
Common shares acquired: 13,797 shares
RSUs exercised: 13,797 units
Common shares held after: 771,682 shares
+3 more
6 metrics
Common shares acquired
13,797 shares
Shares of common stock issued upon RSU conversion on 2026-07-19
RSUs exercised
13,797 units
Restricted stock units converted into common stock on 2026-07-19
Common shares held after
771,682 shares
Direct common stock holdings of Craig A. Collard after the transaction
RSUs held after
82,781 units
Restricted stock units remaining outstanding after the reported conversion
RSU exercise price
$0.0000 per share
Conversion or exercise price for the restricted stock units
Vesting installments
16 installments
RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024
Key Terms
Restricted Stock Units, derivative security, contingent right, vesting
4 terms
Restricted Stock Units financial
"The restricted stock units vest in 16 equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"represents a contingent right to receive one share of common stock"
vesting financial
"The restricted stock units vest in 16 equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Heron Therapeutics (HRTX) report for CEO Craig A. Collard?
Craig A. Collard exercised 13,797 restricted stock units into 13,797 shares of common stock on 2026-07-19. The transaction is reported as an exercise or conversion of a derivative security, with no open-market purchase or sale indicated.
What are the key terms of Craig Collard’s restricted stock units at Heron Therapeutics (HRTX)?
Each restricted stock unit represents a contingent right to receive one share of common stock. These RSUs vest in 16 equal quarterly installments, beginning one quarter after the grant date of 01/19/2024, subject to the original award conditions.
Did the latest Heron Therapeutics (HRTX) insider activity involve an open‑market stock sale?
No. The filing shows a derivative exercise/conversion of restricted stock units into common stock, with net buy/sell shares reported as zero. There is no separate open‑market sale or purchase transaction disclosed for this date.
At what price were the Heron Therapeutics (HRTX) restricted stock units converted to common stock?
The restricted stock units were converted at an exercise price of $0.0000 per share. Each unit equates to one share of common stock, so 13,797 RSUs yielded 13,797 common shares in this non‑cash settlement.
Are Craig Collard’s remaining Heron Therapeutics (HRTX) restricted stock units still vesting?
Yes. After the transaction, 82,781 restricted stock units remain outstanding for Craig A. Collard. According to the award terms, these RSUs vest in 16 equal quarterly installments starting one quarter after the 01/19/2024 grant date.